Compounded GLP-1s after the shortage: what clinics need to know

General information for licensed practices, not legal, regulatory or medical advice. FDA policy here is date sensitive. Every clinical decision rests with your clinic's licensed provider.

This piece supports our complete operator's guide to medical weight management programs.

Why did the shortage matter for compounding?

A GLP-1 receptor agonist is a prescription medication that acts like GLP-1, a hormone the gut releases after eating. While an FDA approved drug is on FDA's drug shortage list, federal law gives compounders more room to make versions of it. When the shortage ends, that room narrows.

Two terms matter:

• 503A pharmacy: a state licensed pharmacy (or physician) compounding for an identified patient based on a prescription.
• 503B outsourcing facility: a compounder registered with FDA under a separate set of rules.

What happened, and when?

All dates are from FDA's statement on GLP-1 compounding policy, as read on Oct 25, 2026:

FDA may post newer updates. Treat this table as a snapshot and check the source page before you act on it.

Is compounded GLP-1 still legal?

Compounding itself is still legal, within conditions. FDA's April 2026 reminder says:

• Under 503A, a pharmacy can't compound "regularly or in inordinate amounts" drugs that are essentially copies of a commercially available drug. FDA describes "essentially a copy" as the same active ingredient in the same, similar or easily substitutable strength, by the same route, unless a prescriber determines and documents a change that produces a significant difference for an identified patient. FDA has said it doesn't intend to take action where a compounder fills four or fewer prescriptions of such a product in a calendar month.
• Under 503B, outsourcing facilities can't compound from a bulk drug substance unless it's on the 503B bulks list or the drug is on FDA's shortage list. FDA states tirzepatide and semaglutide "do not currently appear" on either.
• Adding another ingredient doesn't automatically change the analysis. FDA gives the example of semaglutide combined with vitamin B12 still being considered essentially a copy in some cases.

Whether a particular compounded product fits these conditions is a question for the pharmacy, your provider and your counsel, not for a supplier's marketing.

Are compounded GLP-1s FDA approved?

No. In FDA's words, "Compounded drugs are not approved by FDA." FDA has also published concerns about unapproved GLP-1 drugs, including products sold outside the licensed chain. See Compounding and the FDA: questions and answers for the general rules.

What should a clinic check now?

A short operator checklist:

• Your current GLP-1 source is a licensed pharmacy or registered outsourcing facility, with documents to prove it.
• You know whether each product is FDA approved or compounded, and under 503A or 503B.
• For any 503A compounded product, any clinical need is your provider's genuine, patient-specific judgment, documented in the chart, and never a template added to every order.
• Nothing you stock comes from a "research use only" seller.
• Patient materials and your website never call a compounded product "FDA approved".
• Marketing describes the service, not results, consistent with the FTC's health products guidance.
• Someone owns checking FDA's statement page on a set schedule.

How does sourcing work through RevMed?

Through RevMed, verified clinics order from RevMed's licensed, vetted pharmacy and laboratory partners through the RevMed Portal. License and NPI verification means RevMed checks your clinic's license and each ordering practitioner's National Provider Identifier before you can order. Prescription and compounded products are dispensed only against a valid prescription or order from a licensed practitioner, and product availability may vary by state. These are cash pay services; your clinic pays for its own orders and sets its own patient pricing.

For the wider operating picture, see what is a GLP-1 program? An operator's view. If you're building the service line itself, RevMed's launch team runs a Clinic Launch Program, described as "a done-with-you launch on a fixed 60-day calendar." See clinic launch. No revenue is guaranteed.

Common questions

Is compounded GLP-1 still legal?

Compounding is still legal within the conditions of 503A and 503B. With the shortage resolved, those conditions are tighter. Check FDA's current statement page and ask your pharmacy and counsel.

What changed when the shortage ended?

FDA's temporary enforcement grace periods ended in 2025. 503A pharmacies face limits on essentially copies, and 503B facilities generally can't use these bulk substances.

Are compounded GLP-1s FDA approved?

No. Compounded drugs are not FDA approved, and they shouldn't be described that way.

Can a 503B facility still compound these products?

FDA states tirzepatide and semaglutide aren't currently on the 503B bulks list or the shortage list. Confirm current status on FDA's page.

Who decides whether a patient gets a GLP-1?

Your licensed provider. Staff, suppliers and distributors don't make that call.

Next step

Reviewing your GLP-1 sourcing? Book a 15 minute intro. We're based in Raleigh, your local contact for questions and introductions.